Monday, 08 March 2021

VolitionRx extends clinical trial programme in lung cancer

09 April 2019 | News

The study will be conducted under the supervision of Professor Chen Jin-Shing in the Department of Surgery of National Taiwan University

VolitionRx Limited has announced that it has added to its extensive clinical trial program with the execution of a non-binding Memorandum of Understanding, through its wholly-owned subsidiary, Belgian Volition SPRL, to conduct its first large-scale lung cancer study in conjunction with the prestigious National Taiwan University (NTU). 

The study will be conducted under the supervision of Professor Chen Jin-Shing in the Department of Surgery of NTU and will include 1,200 subjects receiving Low-Dose Computed Tomography scans, including 1,000 with lung cancer.

Professor Chen Jin-Shing commented: "The early data of the Nu.QTM technology platform is promising but clearly larger scale studies are required. Lung cancer remains the deadliest of all the cancers and there is a high unmet clinical need for either a non-invasive early stage lung cancer detection test or for a triage test which can improve the specificity of the Low-Dose CT scan currently used. I very much look forward to collaborating with Volition in evaluating its Nu.QTM technology platform".

Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account